29.Issue 09 september 26 - INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES

Volume : 13, Issue : 09, September – 2026

Title:

NANOTECHNOLOGY-BASED DRUG DELIVERY FOR PRECISION AND PERSONALIZED MEDICINE

Authors :

Balakarishna Talamanchi, Avisa Indira , Chitteti Pujitha, Eeda Mahalakshmi, Doma Pujitha, Chakka.Dimple Naga Rajya Lakshmi, Garikapati Sai Keerthana, Katta Poojitha

Abstract :

Nanotechnology has emerged as an important platform for improving the delivery, targeting, and therapeutic performance of conventional and advanced medicines. Nanocarriers can modify the pharmacokinetic and biodistribution profiles of therapeutic agents, improve solubility and stability, facilitate transport across biological barriers, and enable controlled or stimulus-responsive drug release. These properties are particularly relevant to precision medicine, where treatment is tailored according to disease characteristics, molecular biomarkers, genetic information, and patient-specific responses. Nanoparticles can be engineered by modifying their size, surface charge, composition, architecture, targeting ligands, and responsiveness to biological stimuli. Major nanocarrier systems include liposomes, lipid nanoparticles, polymeric nanoparticles, polymeric micelles, solid lipid nanoparticles, nanostructured lipid carriers, dendrimers, nanocrystals, inorganic nanoparticles, and hybrid nanocarriers. Their applications extend from cancer therapy and gene delivery to RNA therapeutics, neurological disorders, infectious diseases, and theranostics. Recent advances in artificial intelligence, biomarker-guided targeting, and multifunctional nanocarriers are further supporting the development of personalized nanomedicine. However, biological barriers, toxicity, immunogenicity, manufacturing complexity, scale-up, reproducibility, and regulatory requirements continue to limit clinical translation. Overall, nanotechnology provides a flexible platform for developing more selective, controlled, and patient-specific therapeutic strategies.
Keywords: Nanotechnology, nanocarriers, targeted drug delivery, precision medicine, personalized medicine, lipid nanoparticles, gene delivery, RNA therapeutics, theranostics.

Cite This Article:

Please cite this article in press T. Balakrishna et al Nanotechnology-Based Drug Delivery For Precision And Personalized Medicine.,. Indo Am. J. P. Sci, 2026; 13(09).

REFERENCES:

1. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021; 20:101-124.
2. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018; 16:71.
3. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012;63:185-198.
4. Ashley EA. Towards precision medicine. Nat Rev Genet. 2016;17:507-522.
5. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17:20-37.
6. Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. J Control Release. 2011; 153:198-205.
7. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005; 5:161-171.
8. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010; 363:301-304.
9. Ginsburg GS, Phillips KA. Precision medicine: from science to value. Health Aff. 2018; 37:694-701.
10. Mura S, Couvreur P. Nanotheranostics for personalized medicine. Adv Drug Deliv Rev. 2012; 64:1394-1416.
11. Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov. 2014;13:813-827.
12. Anselmo AC, Mitragotri S. Nanoparticles in the clinic. Bioeng Transl Med. 2019; 4:e10143.
13. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013; 65:36-48.
14. Sercombe L, Veerati T, Moheimani F, Wu SY, Sood AK, Hua S. Advances and challenges of liposome assisted drug delivery. Front Pharmacol. 2015;6:286.
15. Sawant RR, Torchilin VP. Challenges in development of targeted liposomal therapeutics. AAPS J. 2012; 14:303-315.
16. Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9:12.
17. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021; 6:1078-1094.
18. Cullis PR, Hope MJ. Lipid nanoparticle systems for enabling gene therapies. Mol Ther. 2017; 25:1467-1475.
19. Kulkarni JA, Cullis PR, van der Meel R. Lipid nanoparticles enabling gene therapies: from concepts to clinical utility. Nucleic Acid Ther. 2018; 28:146-157.
20. Schoenmaker L, Witzigmann D, Kulkarni JA, Verbeke R, Kersten G, Jiskoot W, Crommelin DJA. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int J Pharm. 2021; 601:120586.
21. Cullis PR, Hope MJ. Lipid nanoparticle systems for enabling gene therapies. Mol Ther. 2017; 25:1467-1475.
22. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161:505-522.
23. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers. 2011; 3:1377-1397.
24. Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release. 2001; 73:137-172.
25. Gaucher G, Dufresne MH, Sant VP, Kang N, Maysinger D, Leroux JC. Block copolymer micelles: preparation, characterization and application in drug delivery. J Control Release. 2005; 109:169-188.
26. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161-177.
27. Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002; 54:S131-S155.
28. Svenson S, Tomalia DA. Dendrimers in biomedical applications—reflections on the field. Adv Drug Deliv Rev. 2005; 57:2106-2129.
29. Kesharwani P, Jain K, Jain NK. Dendrimer as nanocarrier for drug delivery. Prog Polym Sci. 2014; 39:268-307.
30. Junghanns JUA, Müller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine. 2008; 3:295-309.
31. Müller RH, Peters K, Becker R, Kruss B. Nanosuspensions for the formulation of poorly soluble drugs. Pharm Technol. 1995; 19:26-44.
32. Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. J Control Release. 2011; 153:198-205.
33. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 1986; 46:6387-6392.
34. Sindhwani S, Syed AM, Ngai J, Kingston NM, Maiorino L, Rothschild JE, et al. The entry of nanoparticles into solid tumours. Nat Mater. 2020; 19:566-575.
35. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer. 2002; 2:750-763.
36. Ruoslahti E. Peptides as targeting elements and tissue penetration devices for nanoparticles. Adv Mater. 2012;24:3747-3756.
37. Bareford LM, Swaan PW. Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev. 2007; 59:748-758.
38. Mura S, Nicolas J, Couvreur P. Stimuli-responsive nanocarriers for drug delivery. Nat Mater. 2013; 12:991-1003.
39. Du JZ, Du XJ, Mao CQ, Wang J. Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery. J Am Chem Soc. 2011; 133:17560-17563.
40. Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov. 2014; 13:813-827.
41. Lee ES, Gao Z, Bae YH. Recent progress in tumor pH targeting nanotechnology. J Control Release. 2008; 132:164-170.
42. de la Rica R, Aili D, Stevens MM. Enzyme-responsive nanoparticles for drug release and diagnostics. Adv Drug Deliv Rev. 2012; 64:967-978.
43. Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018; 15:81-94.
44. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007; 2:751-760.
45. Al-Lawati H, Gordon N, Al-Jabri S, Al-Sharji S, Al-Jabri A, Al-Rashdi S, et al. Nanotechnology-based combination therapy for cancer. Int J Nanomedicine. 2019; 14:8239-8261.
46. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017; 17:20-37.
47. Dowdy SF. Overcoming cellular barriers for RNA therapeutics. Nat Biotechnol. 2017; 35:222-229.
48. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021; 6:1078-1094.
49. Cullis PR, Hope MJ. Lipid nanoparticle systems for enabling gene therapies. Mol Ther. 2017; 25:1467-1475.
50. Patel A, Kaczmarek JC, Bose S, Kauffman KJ, Mir F, Heartlein MW, et al. Inhaled nanoparticle-mediated mRNA therapy for respiratory diseases. Nat Mater. 2019; 18:996-1004.
51. Manzari MT, Shamay Y, Kiguchi H, Rosen N, Scaltriti M, Heller DA. Targeted drug delivery strategies for precision medicines. Nat Rev Mater. 2021;6:351-370.
52. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021; 20:101-124.
53. Mura S, Couvreur P. Nanotheranostics for personalized medicine. Adv Drug Deliv Rev. 2012; 64:1394-1416.
54. Xie J, Lee S, Chen X. Nanoparticle-based theranostic agents. Adv Drug Deliv Rev. 2010; 62:1064-1079.
55. Kelkar SS, Reineke TM. Theranostics: combining imaging and therapy. Bioconjug Chem. 2011; 22:1879-1903.
56. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005; 2:3-14.
57. Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: overcoming blood-brain barrier to treat neurodegenerative diseases. J Control Release. 2016; 235:34-47.
58. Neves V, Mak SY, Moutinho CG, Ferreira D, Loureiro JA, Barata D, et al. Overcoming the blood-brain barrier: focus on nanosystems. J Control Release. 2021;332:152-169.
59. Illum L. Nasal drug delivery—possibilities, problems and solutions. J Control Release. 2003; 87:187-198.
60. Pelgrift RY, Friedman AJ. Nanotechnology as a therapeutic tool to combat microbial resistance. Adv Drug Deliv Rev. 2013; 65:1803-1815.
61. Makabenta JMA, Nabawy A, Li CH, Schmidt-Malan S, Patel R, Rotello VM. Nanomaterial-based therapeutics for antibiotic-resistant bacterial infections. Nat Rev Microbiol. 2021; 19:23-36.
62. Malkawi AK, Al-Ghananeem AM, Alhussain H, et al. Artificial intelligence and machine learning in nanomedicine and drug delivery. Pharmaceutics. 2024; 16..
63. Manzari MT, Shamay Y, Kiguchi H, Rosen N, Scaltriti M, Heller DA. Targeted drug delivery strategies for precision medicines. Nat Rev Mater. 2021; 6:351-370.
64. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015; 33:941-951.
65. Monopoli MP, Åberg C, Salvati A, Dawson KA. Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol. 2012; 7:779-786.
66. Fadeel B. Hide and seek: nanomaterial visibility in the immune system. Toxicol Appl Pharmacol. 2019; 372:137-147.
67. Anselmo AC, Mitragotri S. Nanoparticles in the clinic. Bioeng Transl Med. 2019; 4:e10143.
68. Ventola CL. Progress in nanomedicine: approved and investigational nanodrugs. P T. 2017; 42:742-755.
69. Ferrari M. Frontiers in cancer nanomedicine: directing nanocarriers to the tumor. Pharmacol Res. 2020; 155:104699.
70. Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov. 2014; 13:813-827.
71. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021; 20:101-124.